...
首页> 外文期刊>Journal of cataract and refractive surgery >One year results of European Multicenter Study of intrastromal corneal ring segments. Part 1: refractive outcomes.
【24h】

One year results of European Multicenter Study of intrastromal corneal ring segments. Part 1: refractive outcomes.

机译:欧洲多中心基质角膜内环段研究的一年结果。第1部分:屈光结果。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: To assess the efficacy, predictability, stability, and safety of correcting myopia with intrastromal corneal ring segments (ICRS, KeraVision, Inc.). SETTING: Twelve European investigational sites. METHODS: Patients with myopia of -1.0 to -6.0 diopters (D) and best spectacle-corrected visual acuity (BSCVA) of 20/20 or better (except in 3 eyes) were assigned to receive 1 of 5 ICRS thicknesses (0.25, 0.30, 0.35, 0.40, or 0.45 mm). Efficacy was assessed by postoperative uncorrected visual acuity (UCVA), predictability of refractive outcome (deviation from predicted cycloplegic refraction spherical equivalent), and stability of refractive effect (manifest refraction spherical equivalent [MRSE]). Safety was assessed by maintenance or loss of preoperative BSCVA and induced manifest refraction cylinder. Measurements were made preoperatively and 1 and 7 days and 1, 2, 3, 6, and 12 months postoperatively. RESULTS: One hundred fifty-nine ICRSs were implanted in the eyes of 107 patients (52 patients had bilateral implantation). Preoperatively, UCVA was worse than 20/40 in 98% of eyes (155/159); 12 months postoperatively, it was 20/20 or better in 63% of eyes (83/132) and 20/40 or better in 96% (127/132). Predicted refractive corrections for each ICRS thickness generally correlated with achieved corrections. At 12 months postoperatively, 90% of eyes (124/138) were within +/-1.00 D of plano (MRSE). Two or more lines of BSCVA were lost in 6% of eyes (8/135); all 8 eyes had BSCVAs of 20/25 or better. CONCLUSION: The ICRS safely, effectively, and predictably reduced or eliminated low to moderate myopia. Refractive correction was stable through the 12 month follow-up.
机译:目的:评估使用基质内角膜环段矫正近视的功效,可预测性,稳定性和安全性(ICRS,KeraVision,Inc.)。地点:十二个欧洲研究地点。方法:将近视度数为-1.0至-6.0屈光度(D),最佳眼镜矫正视力(BSCVA)为20/20或更高(3眼除外)的患者接受5种ICRS厚度之一(0.25、0.30) ,0.35、0.40或0.45毫米)。通过术后未矫正视力(UCVA),屈光结果的可预测性(与预期的睫状肌麻痹性屈光度当量球偏度)和屈光效果的稳定性(明显屈光度当量球度[MRSE])来评估疗效。通过术前BSCVA的维持或丢失以及明显的屈光度数评估安全性。术前,术后1天,7天,1、2、3、6和12个月进行测量。结果:107例患者的眼睛中植入了159例ICRS(52例患者进行了双侧植入)。术前,98%的眼睛的UCVA低于20/40(155/159);术后12个月,有63%的眼睛(83/132)为20/20或更好,有96%(127/132)的眼睛为20/40或更好。每种ICRS厚度的预测屈光校正通常与已实现的校正相关。术后12个月,90%的眼睛(124/138)处于平视(MRSE)+/- 1.00 D以内。 6%的眼睛损失了两行或更多行BSCVA(8/135);所有8只眼的BSCVA均为20/25或更高。结论:ICRS安全,有效且可预测地减少或消除了中低度近视。在12个月的随访中,屈光矫正稳定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号